Coherus Oncology, Inc.
CHRSNASDAQHealthcare● Active
$1.42
$-0.03(-2.07%)
Market Cap$173822088
P/E Ratio—
52W High$2.616
52W Low$0.71
Coherus Oncology, Inc. (CHRS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CHRS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $42.17M | $266.96M | $257.24M | $211.04M | $326.55M |
| Cost of Revenue | $17.74M | $117.55M | $158.99M | $70.08M | $57.59M |
| Gross Profit | $24.43M | $149.41M | $98.25M | $140.96M | $268.96M |
| Gross Margin %(computed) | 57.94% | 55.97% | 38.19% | 66.79% | 82.36% |
| Operating Expenses | |||||
| R&D Expenses | $104.96M | $93.34M | $109.44M | $199.36M | $363.11M |
| G&A Expenses | $0.00M | $139.54M | $174.72M | $187.98M | $161.01M |
| Total Operating Expenses | $203.97M | $261.07M | $301.45M | $397.84M | $532.82M |
| Operating Income | ($179.53M) | ($111.67M) | ($203.20M) | ($256.88M) | ($263.86M) |
| Operating Margin %(computed) | -425.72% | -41.83% | -78.99% | -121.72% | -80.80% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $9.00M | $27.16M | $40.54M | $32.47M | $22.96M |
| Income Before Tax | ($183.12M) | $28.51M | ($238.27M) | ($291.75M) | ($287.10M) |
| Income Tax Expense | $0.00M | $0.00M | ($0.38M) | $0.00M | $0.00M |
| Net Income | ($170.29M) | $28.51M | ($237.89M) | ($291.75M) | ($287.10M) |
| Net Margin %(computed) | -403.80% | 10.68% | -92.48% | -138.24% | -87.92% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.45 | $0.25 | $-2.53 | $-3.76 | $-3.81 |
| Wtd Avg Shares | 120.37M | 114.55M | 94.16M | 77.63M | 75.45M |
| EBITDA | ($175.61M) | $60.94M | ($193.94M) | ($255.58M) | ($260.69M) |
| EBITDA Margin %(computed) | -416.41% | 22.83% | -75.39% | -121.10% | -79.83% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Coherus Oncology, Inc. data
About Coherus Oncology, Inc. (CHRS) Income Statement
Coherus Oncology, Inc. (CHRS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CHRS reported revenue of $0.04B, gross profit of $0.02B (gross margin 57.94%), and net income of ($0.17B) — a net profit margin of -403.80%.
Frequently asked questions
CHRS · 4 questionsCoherus Oncology, Inc. (CHRS) reported revenue of $0.04B for 2025, down 84.2% year-over-year.
CHRS revenueCHRS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08